CARM1 inhibitors and uses thereof

US9346802B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9346802-B2
Application numberUS-201414210672-A
CountryUS
Kind codeB2
Filing dateMar 14, 2014
Priority dateMar 15, 2013
Publication dateMay 24, 2016
Grant dateMay 24, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Provided herein are compounds of Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X, R 1 , R 2a , R 2b , R 2c , R 2d , are as defined herein, and Ring HET is a 6-membered monocyclic heteroaryl ring system of formula: wherein L 2 , R 13 , G 8 , G 10 , G 11 , and G 12 are as defined herein. Compounds of the present invention are useful for inhibiting CARM1 activity. Methods of using the compounds for treating CARM1-mediated disorders are also described.

First claim

Opening claim text (preview).

What is claimed is: 1. A compound of Formula (I): or a pharmaceutically acceptable salt thereof; wherein: X is —O—, —S—, or —CH 2 —; R 1 is hydrogen or optionally substituted C 1-4 aliphatic; each of R 2a , R 2b , R 2c , and R 2d is independently hydrogen, halogen, —CN, —NO 2 , —C(═O)R A2 , —C(═O)OR A2 , —C(═O)N(R A2 ) 2 , —OR A2 , —SR A , —N(R A2 ) 2 , —S(═O)R A2 , —S(═O) 2 R A2 , optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, or optionally substituted heterocyclyl, wherein each instance of R A2 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R A2 groups attached to the same nitrogen atom are joined to form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring; Ring HET is a 6-membered monocyclic heteroaryl ring system of the formula: each instance of R 8 , R 10 , R 11 , and R 12 is independently selected from the group consisting of hydrogen, halo, —CN, —NO 2 , —C(═O)R′, —C(═O)OR′, —C(═O)N(R′) 2 , optionally substituted alkyl, and -L 1 -R 3 ; each instance of R′ is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R′ groups attached to the same nitrogen are joined to form an optionally substituted heterocyclyl ring or optionally substituted heteroaryl ring; each instance of L 1 and L 2 is independently a bond, —O—, —N(R L )—, —S—, —C(O)—, —C(O)O—, —C(O)S—, —C(O)N(R L )—, —C(O)N(R L )N(R L )—, —OC(O)—, —OC(O)N(R L )—, —NR L C(O)—, —NR L C(O)N(R L )—, —NR L C(O)N(R L )N(R L )—, —NR L C(O)O—, —SC(O)—, —C(═NR L )—, —C(═NNR L )—, —C(═NOR L )—, —C(═NR L )N(R L )—, —NR L C(═NR L )—, —C(S)—, —C(S)N(R L )—, —NR L C(S)—, —S(O)—, —OS(O) 2 —, —S(O) 2 O—, —SO 2 —, —N(R L )SO 2 —, —SO 2 N(R L )—, —N(R L )SO 2 N(R L )—, or an optionally substituted C 1-10 saturated or unsaturated hydrocarbon chain, wherein one or more moieties selected from the group consisting of —O—, —N(R L )—, —S—, —C(O)—, —C(O)O—, —C(O)S—, —C(O)N(R L )—, —C(O)N(R L )N(R L )—, —OC(O)—, —OC(O)N(R L )—, —NR L C(O)—, —NR L C(O)N(R L )—, —NR L C(O)N(R L )N(R L )—, —NR L C(O)O—, —SC(O)—, —C(═NR L )—, —C(═NNR L )—, —C(═NOR L )—, —C(═NR L )N(R L )—, —NR L C(═NR L )—, —C(S)—, —C(S)N(R L )—, —NR L C(S)—, —S(O)—, —OS(O) 2 —, —S(O) 2 O—, —SO 2 —, —N(R L )SO 2 —, —SO 2 N(R L )—, and —N(R L )SO 2 N(R L )— is optionally and independently present between two carbon atoms of the hydrocarbon chain, and is optionally and independently present at one or both ends of the hydrocarbon chain; each R L is independently hydrogen, optionally substituted alkyl, or a nitrogen protecting group, or R L and R 3 taken together form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring, or R L and R 13 taken together form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring; R 3 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, provided when R 3 is hydrogen, then L 1 is not a bond; and R 13 is optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. 2. The compound of claim 1 , wherein X is —O—. 3. The compound of claim 1 , wherein X is —S— or —CH 2 —. 4. The compound of claim 1 , wherein Ring HET is: 5. The compound of claim 1 , wherein Ring HET is: 6. The compound of claim 1 , wherein R 1 is hydrogen, methyl, ethyl, n-propyl, isopropyl, or cyclopropyl. 7. The compound of claim 1 , wherein R 2a , R 2b , and R 2d are hydrogen. 8. The compound of claim 1 , wherein at least one of R 2a , R 2b , R 2c , and R 2d is halo. 9. The compound of claim 1 , wherein L 2 is a bond, —N(R L )—, —NR L C(O)O—, —NR L C(O)N(R L )—, —N(R L )—, —N(R L )SO 2 N(R L )—, —NR L —(CH 2 ) x —C(O)O—, —NR L —(CH 2 ) x —O—, —NR L C(O)N(R L )—, —NR L —(CH 2 ) x —, —(CH 2 ) x —NR L —, —NR L C(O)O(CH 2 ) x —, —NR L C(O)NR L (CH 2 ) x —, or —NR L (CH 2 ) x NR L C(O)—, wherein x is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. 10. The compound of claim 1 , wherein R 13 is selected from the group consisting of: wherein: each instance of independently represents a single or double bond; m is 0, 1, 2, or 3; each instance of R 13A is independently hydroxyl, substituted hydroxyl, thiol, substituted thiol, amino, substituted amino, carbonyl, sulfonyl, sulfinyl, —CN, —NO 2 , halogen, or optionally substituted alkyl, or two R 13A groups are joined to form an optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl, or optionally substituted heteroaryl ring, or R 13A and R 13B group are joined to form an optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl, or optionally substituted heteroaryl ring; and R 3B and R 13B are independently hydrogen, optionally substituted alkyl, or a nitrogen protecting group. 11. The compound of claim 1 , wherein Ring HET comprises a group -L 1 -R 3 is attached thereto. 12. The compound of claim 11 , wherein L 1 is a bond, —N(R L )—, —NR L C(O)O—, —NR L C(O)N(R L )—, —N(R L )—, —N(R L )SO 2 N(R L )—, —NR L —(CH 2 ) x —C(O)O—, —NR L —(CH 2 ) x —O—, —NR L C(O)N(R L )—, —NR L —(CH 2 ) x —, —(CH 2 ) x —NR L —, —NR L C(O)O (CH 2 ) x —, —NR L C(O)NR L (CH 2 ) x —, or —NR L (CH 2 ) x NR L C(O)—, wherein x is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. 13. The compound of claim 11 , wherein R 3 is selected from the group consisting of: wherein: each instance of independently represents a single or double bond; n is 0, 1, 2, or 3; each instance of R 3A is independently hydroxyl, substituted hydroxyl, thiol, substituted thiol, amino, substituted amino, carbonyl, sulfonyl, sulfinyl, —CN, —NO 2 , halogen, or optionally substituted alkyl, or two R 3A groups are joined to form an optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl,

Assignees

Inventors

Classifications

  • directly linked by a ring-member-to-ring-member bond · CPC title

  • One nitrogen atom (nitro radicals C07D239/30) · CPC title

  • directly linked by a ring-member-to-ring-member bond · CPC title

  • C07D471/04Primary

    Ortho-condensed systems · CPC title

  • directly linked by a ring-member-to-ring-member bond · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9346802B2 cover?
Provided herein are compounds of Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X, R 1 , R 2a , R 2b , R 2c , R 2d , are as defined herein, and Ring HET is a 6-membered monocyclic heteroaryl ring system of formula: wherein L 2 , R 13 , G 8 , G 10 , G 11 , and G 12 are as defined…
Who is the assignee on this patent?
Epizyme Inc
What technology area does this patent fall under?
Primary CPC classification C07D471/04. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue May 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).